Moreover, the 1-, 3-, and 5-year tumor-free survival rates of the patients in the high-SMPDL3A expression group were significantly lower than those in the high-SMPDL3A expression group (P = 0.0092; Figure 3E). This evidence concerns the gene SMPDL3A and neoplasm.